Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia.
Author(s): Raad I, Bompart F, Hachem R
Affiliation(s): Department of Medical Specialties, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Publication date & source: 1999-03, Eur J Clin Microbiol Infect Dis., 18(3):199-202.
Publication type: Clinical Trial; Clinical Trial, Phase II; Randomized Controlled Trial
Two different doses of quinupristin/dalfopristin were compared with intravenous vancomycin with regard to the efficacy and safety in the treatment of catheter-related staphylococcal bacteremia. A total of 39 patients were enrolled from 13 centers. For all treated patients with a baseline pathogen, outcome was comparable for all antibiotic study regimens. Discontinuation of the antibiotic for an adverse clinical event occurred in 12% of patients receiving quinupristin/dalfopristin and in 15% of those receiving vancomycin. Quinupristin/dalfopristin may have the potential to serve as an alternative agent in the treatment of catheter-related staphylococcal bacteremia. However, larger prospective randomized trials are required.